On January 4, 2024 Halia Therapeutics, a clinical-stage biopharmaceutical company, is pioneering a novel class of small molecule medications designed to combat inflammation, reported that its leadership team will attend the 42nd JP Morgan Healthcare Conference (January 8 – 11) and present at Biotech Showcase 2024 (January 8–10) in San Francisco (Press release, Halia Therapeutics, JAN 4, 2024, View Source [SID1234638972]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities.
At the Showcase, Halia Therapeutics will discuss its lead product, HT-6184, which inhibits chronic inflammation associated with multiple diseases. A Phase II clinical trial to evaluate HT-6184 was recently initiated to treat patients with lower-risk myelodysplastic syndromes. This year, registered attendees can view Halia’s presentation live and access a recorded version currently available.
Presentation details at Biotech Showcase:
Category Listing: Inflammation, Oncology, Neurology
Speaker: Margit Janat-Amsbury, M.D., Ph.D., Chief Medical Officer of Halia Therapeutics
Date: January 9, 2024
Time: 10:15 a.m. PT
Location: Hilton San Francisco Union Square, 333 O’Farrell St, San Francisco, CA 94102 (Franciscan-B)